AC
HRTX icon

Aristides Capital’s Heron Therapeutics HRTX Stock Holding History

Aristides Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,849
Closed -$80.9K – 273
2024
Q4 		$80.9K Buy
+52,849
New +$85.7K 0.02% 288

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aristides Capital's HRTX Position: Q1 2025 in Review

Aristides Capital sold out of Heron Therapeutics (HRTX) in Q1 2025, closing a stake of 52,849 shares — an estimated $80.9K sold.

Aristides Capital first reported a position in HRTX in Q4 2024 and held it in 1 quarter. The position peaked at $80.9K in Q4 2024. 164 funds tracked by Wall St. Rank hold HRTX as of Q1 2025.

  • Aristides Capital reported no remaining Heron Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Aristides Capital sold 52,849 Heron Therapeutics shares in Q1 2025, an estimated $80.9K.
  • Aristides Capital first reported a position in Heron Therapeutics in Q4 2024 and held it in 1 quarter.
  • Aristides Capital's Heron Therapeutics position peaked at $80.9K in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.